CG Oncology Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
CGON$72.64-2.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating Activities | ||
| Net loss | $(16,932) | $(8,667) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 4 | 4 |
| Amortization of loan fees | — | 7 |
| Final payment amortization | — | 112 |
| Success fee amortization | — | (335) |
| Stock-based compensation expense | 1,517 | 179 |
| (Accretion of discount) amortization of premium on short-term investments | (2,199) | — |
| Non-cash lease expense | (3) | 341 |
| Changes in operating assets and liabilities: | ||
| Prepaid and current assets | (5,654) | 224 |
| Other assets | (33) | — |
| Accounts payable | 1,417 | (9) |
| Accrued expenses | (4,129) | 158 |
| Net cash used in operating activities | (26,012) | (7,986) |
| Investing Activities | ||
| Proceeds from sales and maturities of short-term investments | 145,865 | — |
| Purchase of short-term investments | (453,297) | (78,699) |
| Purchase of property and equipment | (12) | — |
| Net cash used in investing activities | (307,444) | (78,699) |
| Financing Activities | ||
| Proceeds from initial public offering, net of issuance costs | 406,410 | — |
| Payments of success fee or long-term debt | (365) | (833) |
| Proceeds from exercise of stock options | — | 68 |
| Deferred offering costs | (3,387) | — |
| Net cash provided by (used in) financing activities | 402,658 | (765) |
| Net increase (decrease) in cash, cash equivalent and restricted cash | 69,202 | (87,450) |
| Cash, cash equivalents and restricted cash at beginning of year | 8,266 | 88,143 |
| Cash, cash equivalents and restricted cash at end of period | $77,468 | $693 |
| Supplemental Disclosure of Cash Flow Information | ||
| Cash paid for interest | $— | $271 |
| Cash paid for taxes | $— | $— |
| Supplemental Schedule of Noncash Investing and Financing Activities: | ||
| Reclassification of 38,413,909 redeemable convertible preferred stock to 38,413,909 shares of common stock | $307,890 | $— |
| Reclassification of deferred offering costs | $6,845 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.